Titre : Gènes switch

Gènes switch : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Gènes switch : Questions médicales les plus fréquentes", "headline": "Gènes switch : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Gènes switch : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-19", "dateModified": "2025-03-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Gènes switch" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Gènes régulateurs", "url": "https://questionsmedicales.fr/mesh/D005809", "about": { "@type": "MedicalCondition", "name": "Gènes régulateurs", "code": { "@type": "MedicalCode", "code": "D005809", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340.425" } } }, "about": { "@type": "MedicalCondition", "name": "Gènes switch", "alternateName": "Genes, Switch", "code": { "@type": "MedicalCode", "code": "D005812", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Martin Fussenegger", "url": "https://questionsmedicales.fr/author/Martin%20Fussenegger", "affiliation": { "@type": "Organization", "name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland; University of Basel, Faculty of Life Science, Basel, Switzerland. Electronic address: fussenegger@bsse.ethz.ch." } }, { "@type": "Person", "name": "Ana Palma Teixeira", "url": "https://questionsmedicales.fr/author/Ana%20Palma%20Teixeira", "affiliation": { "@type": "Organization", "name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland." } }, { "@type": "Person", "name": "Jin Wang", "url": "https://questionsmedicales.fr/author/Jin%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Physics and Applied Mathematics, State University of New York at Stony Brook, Stony Brook, New York 11794, USA." } }, { "@type": "Person", "name": "Jörg S Hartig", "url": "https://questionsmedicales.fr/author/J%C3%B6rg%20S%20Hartig", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany; Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany. Electronic address: joerg.hartig@uni-konstanz.de." } }, { "@type": "Person", "name": "Omer Gokcumen", "url": "https://questionsmedicales.fr/author/Omer%20Gokcumen", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 + T lymphocytes.", "datePublished": "2022-08-05", "url": "https://questionsmedicales.fr/article/35930205", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00018-022-04481-1" } }, { "@type": "ScholarlyArticle", "name": "The significance of the microlymphangiogenesis, microangiogenesis, and combined detection of programmed cell death-1 protein (PD-1)/ki67 in gastric cancer tissues.", "datePublished": "2023-05-13", "url": "https://questionsmedicales.fr/article/37179266", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00432-023-04709-y" } }, { "@type": "ScholarlyArticle", "name": "Are programmed cell death protein-1 and Angiopoietins-2 effective biomarkers for detection the severity of psoriatic patients?", "datePublished": "2022-05-25", "url": "https://questionsmedicales.fr/article/35506216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jocd.15039" } }, { "@type": "ScholarlyArticle", "name": "The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1", "datePublished": "2022-07-22", "url": "https://questionsmedicales.fr/article/35935985", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.830606" } }, { "@type": "ScholarlyArticle", "name": "Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment.", "datePublished": "2023-02-17", "url": "https://questionsmedicales.fr/article/36801909", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-29971-5" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Génome", "item": "https://questionsmedicales.fr/mesh/D016678" }, { "@type": "ListItem", "position": 5, "name": "Composants de génome", "item": "https://questionsmedicales.fr/mesh/D040481" }, { "@type": "ListItem", "position": 6, "name": "Gènes", "item": "https://questionsmedicales.fr/mesh/D005796" }, { "@type": "ListItem", "position": 7, "name": "Gènes régulateurs", "item": "https://questionsmedicales.fr/mesh/D005809" }, { "@type": "ListItem", "position": 8, "name": "Gènes switch", "item": "https://questionsmedicales.fr/mesh/D005812" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Gènes switch - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Gènes switch", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Gènes switch", "description": "Comment identifier un gène switch ?\nQuels tests sont utilisés pour les gènes switch ?\nLes gènes switch sont-ils visibles sur une analyse génétique ?\nPeut-on détecter des mutations dans les gènes switch ?\nQuels marqueurs sont associés aux gènes switch ?", "url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Gènes switch", "description": "Quels symptômes sont liés aux gènes switch ?\nLes gènes switch affectent-ils le développement ?\nPeut-on observer des anomalies dues aux gènes switch ?\nLes gènes switch influencent-ils le comportement ?\nY a-t-il des symptômes neurologiques associés ?", "url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Gènes switch", "description": "Peut-on prévenir les maladies liées aux gènes switch ?\nQuels modes de vie peuvent aider à prévenir ces maladies ?\nLes conseils génétiques sont-ils utiles ?\nY a-t-il des vaccins pour prévenir les effets des gènes switch ?\nComment le suivi médical contribue-t-il à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Gènes switch", "description": "Comment traiter les dysfonctionnements des gènes switch ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des essais cliniques pour ces traitements ?\nLes traitements sont-ils efficaces ?\nQuels effets secondaires peuvent survenir ?", "url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Gènes switch", "description": "Quelles complications peuvent survenir avec les gènes switch ?\nLes gènes switch peuvent-ils causer des maladies héréditaires ?\nY a-t-il des risques de transmission familiale ?\nLes complications sont-elles réversibles ?\nComment les gènes switch affectent-ils la longévité ?", "url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Gènes switch", "description": "Quels facteurs de risque sont associés aux gènes switch ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il les gènes switch ?\nLes facteurs génétiques jouent-ils un rôle ?\nLes infections peuvent-elles affecter les gènes switch ?", "url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un gène switch ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par des techniques comme le séquençage et l'analyse d'expression génique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les gènes switch ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de PCR et des analyses de microarray sont couramment utilisés." } }, { "@type": "Question", "name": "Les gènes switch sont-ils visibles sur une analyse génétique ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être détectés indirectement par l'expression des gènes qu'ils régulent." } }, { "@type": "Question", "name": "Peut-on détecter des mutations dans les gènes switch ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations peuvent être identifiées par séquençage ciblé." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux gènes switch ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs épigénétiques comme les méthylations peuvent indiquer leur activité." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux gènes switch ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon les gènes régulés, incluant des troubles métaboliques." } }, { "@type": "Question", "name": "Les gènes switch affectent-ils le développement ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils jouent un rôle crucial dans le développement embryonnaire et cellulaire." } }, { "@type": "Question", "name": "Peut-on observer des anomalies dues aux gènes switch ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies peuvent se manifester par des malformations congénitales ou des cancers." } }, { "@type": "Question", "name": "Les gènes switch influencent-ils le comportement ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains gènes switch peuvent affecter des traits comportementaux et cognitifs." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certaines dysrégulations peuvent entraîner des troubles neurologiques variés." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées aux gènes switch ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par le dépistage génétique et des interventions précoces." } }, { "@type": "Question", "name": "Quels modes de vie peuvent aider à prévenir ces maladies ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est bénéfique." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils utiles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conseils génétiques aident à évaluer les risques et à planifier des actions préventives." } }, { "@type": "Question", "name": "Y a-t-il des vaccins pour prévenir les effets des gènes switch ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour les gènes switch." } }, { "@type": "Question", "name": "Comment le suivi médical contribue-t-il à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier permet de détecter précocement des anomalies et d'intervenir rapidement." } }, { "@type": "Question", "name": "Comment traiter les dysfonctionnements des gènes switch ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments ciblés peuvent être utilisés." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques pour ces traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux essais cliniques explorent des thérapies pour les gènes switch." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité varie selon le type de gène switch et la pathologie associée." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires peuvent inclure des réactions immunitaires ou des complications." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les gènes switch ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des cancers, des troubles métaboliques et des malformations." } }, { "@type": "Question", "name": "Les gènes switch peuvent-ils causer des maladies héréditaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains gènes switch sont impliqués dans des maladies héréditaires complexes." } }, { "@type": "Question", "name": "Y a-t-il des risques de transmission familiale ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les gènes switch peuvent être transmis et affecter plusieurs membres d'une famille." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Comment les gènes switch affectent-ils la longévité ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des dysfonctionnements peuvent réduire l'espérance de vie en augmentant le risque de maladies." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés aux gènes switch ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs environnementaux, génétiques et comportementaux peuvent influencer leur activité." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge peut affecter l'expression des gènes switch et le risque de maladies." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il les gènes switch ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes comme le tabagisme ou l'alimentation peuvent moduler leur activité." } }, { "@type": "Question", "name": "Les facteurs génétiques jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des variations génétiques peuvent prédisposer à des dysfonctionnements des gènes switch." } }, { "@type": "Question", "name": "Les infections peuvent-elles affecter les gènes switch ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent altérer l'expression des gènes switch et provoquer des maladies." } } ] } ] }

Sources (10000 au total)

The significance of the microlymphangiogenesis, microangiogenesis, and combined detection of programmed cell death-1 protein (PD-1)/ki67 in gastric cancer tissues.

To investigate the relationship between the microlymphangiogenesis, microangiogenesis, and combined detection of the programmed cell death-1 protein (PD-1)/ki67 in patients with gastric cancer as well... Immunohistochemistry was used to detect the microlymphatic density (MLD) and microvessel density (MVD) in the central and peripheral zones in 92 cases of gastric cancer, along with the number of PD-1-... The central zone of the gastric cancer tissue contained fewer atretic cord-like lymphatic vessels than the peripheral zone, while the peripheral zone contained an increased number of lymphatic vessels... The detection of the MLD and MVD as well as the positive expression of PD-1 and ki67 in gastric cancer tissue are important reference indicators for judging the prognosis of gastric cancer....

Are programmed cell death protein-1 and Angiopoietins-2 effective biomarkers for detection the severity of psoriatic patients?

Early detection of psoriasis is still an open discussion. Psoriatic lesions are characterized by red/scaly plaques affecting different body-sites.... To evaluate the levels of programmed cell death protein-1(PD-1) and Angiopoietins-2(Ang-2) in serum, lesional, and perilesional of psoriatic patients and correlate them with controls and disease sever... Serum samples were obtained from 40 participants subdivided equally into psoriatic and healthy controls, 4 mm punch_biopsy equally from lesional and perilesional skin of individuals. PD-1/ANG-2 ELISA ... Serum and tissue levels of PD-1 and Ang-2 were overexpressed in psoriatic patients compared with controls. There was a statistical difference between patients and controls in level of PD-1(serum and t... PD-1 and ANG-2 can be highly recommended to determine the severity of psoriasis....

Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment.

Programmed cell death protein 1 (PD-1)-expressing T cells are expanded in individuals with established rheumatoid arthritis (RA). However, little is known about their functional role in the pathogenes...

A binary module for microbiota-mediated regulation of γδ17 cells, hallmarked by microbiota-driven expression of programmed cell death protein 1.

Little is known about how microbiota regulate innate-like γδ T cells or how these restrict their effector functions within mucosal barriers, where microbiota provide chronic stimulation. Here, we show...

Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma.

Esophagogastric adenocarcinoma (EGA) is one of the leading causes of cancer-related mortality worldwide. Therapeutic options are limited for patients with recurrent or metastatic disease. Targeted the... Here, a 52-year-old male patient with advanced EGA Siewert Type II shows a significant response to combination therapy with olaparib and pembrolizumab. After progression following first- and second-li... In this case, a long-lasting response to the combination of olaparib and pembrolizumab was observed despite previous treatment with a PD-L1 inhibitor. This case illustrates the need for further clinic...

An Immunochromatographic Test Strip for Rapid Quantitative Control of Monoclonal Antibodies against Programmed Cell Death Protein 1.

Cancer is one of the major public health challenges in the world, which is characterized by rapid progression and high mortality. Immunotherapy, represented by PD-1 monoclonal antibody, has significan...